JP2015535237A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535237A5
JP2015535237A5 JP2015538612A JP2015538612A JP2015535237A5 JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5 JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5
Authority
JP
Japan
Prior art keywords
composition
phosphate
citrate buffer
pharmaceutical composition
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535237A (ja
JP6431844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/059612 external-priority patent/WO2014064637A1/en
Publication of JP2015535237A publication Critical patent/JP2015535237A/ja
Publication of JP2015535237A5 publication Critical patent/JP2015535237A5/ja
Application granted granted Critical
Publication of JP6431844B2 publication Critical patent/JP6431844B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538612A 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物 Expired - Fee Related JP6431844B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1236KO2012 2012-10-26
IN1236/KOL/2012 2012-10-26
IN1235KO2012 2012-10-26
IN1235/KOL/2012 2012-10-26
PCT/IB2013/059612 WO2014064637A1 (en) 2012-10-26 2013-10-24 Stable pharmaceutical composition of tnfr:fc fusion protein

Publications (3)

Publication Number Publication Date
JP2015535237A JP2015535237A (ja) 2015-12-10
JP2015535237A5 true JP2015535237A5 (cg-RX-API-DMAC7.html) 2016-12-15
JP6431844B2 JP6431844B2 (ja) 2018-11-28

Family

ID=54208810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538612A Expired - Fee Related JP6431844B2 (ja) 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物

Country Status (14)

Country Link
US (2) US10058589B2 (cg-RX-API-DMAC7.html)
EP (1) EP2919801B1 (cg-RX-API-DMAC7.html)
JP (1) JP6431844B2 (cg-RX-API-DMAC7.html)
KR (1) KR102132050B1 (cg-RX-API-DMAC7.html)
CN (1) CN104936607A (cg-RX-API-DMAC7.html)
AU (1) AU2013336279B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015009462A2 (cg-RX-API-DMAC7.html)
CA (1) CA2889271A1 (cg-RX-API-DMAC7.html)
ES (1) ES2806946T3 (cg-RX-API-DMAC7.html)
MX (1) MX366622B (cg-RX-API-DMAC7.html)
PL (1) PL2919801T3 (cg-RX-API-DMAC7.html)
PT (1) PT2919801T (cg-RX-API-DMAC7.html)
RU (1) RU2664691C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014064637A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス.アー. TNFR:Fc融合ポリペプチドの代替配合物
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
JP6884858B2 (ja) * 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
KR20200038507A (ko) * 2017-08-08 2020-04-13 체에스엘 베링 아게 헤모펙신 제형
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
WO2022264097A1 (en) 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
ES2223017T5 (es) * 1997-09-23 2010-10-15 Rentschler Biotechnologie Gmbh Formulaciones liquidas de un interferon beta.
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PL213501B1 (pl) 2003-02-28 2013-03-29 Ares Trading Sa Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
WO2009133529A2 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Processes for refolding of insulin
CN104490767A (zh) * 2009-05-04 2015-04-08 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
ES2684921T3 (es) 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
US8821865B2 (en) * 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
ES2759931T3 (es) * 2011-04-20 2020-05-12 Sandoz Ag Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc

Similar Documents

Publication Publication Date Title
JP2015535237A5 (cg-RX-API-DMAC7.html)
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
JP2019536761A5 (cg-RX-API-DMAC7.html)
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
JP2015527402A5 (cg-RX-API-DMAC7.html)
JP2019504086A5 (cg-RX-API-DMAC7.html)
JP2012515221A5 (cg-RX-API-DMAC7.html)
FI3209681T3 (fi) Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä
JP2022166006A5 (cg-RX-API-DMAC7.html)
JP2010529999A5 (cg-RX-API-DMAC7.html)
JP2013521296A5 (cg-RX-API-DMAC7.html)
RU2020112952A (ru) Жидкая фармацевтическая композиция
JP2013543505A5 (cg-RX-API-DMAC7.html)
JP2011502968A5 (cg-RX-API-DMAC7.html)
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
RU2015132431A (ru) Составы, содержащие антитела
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
JP2019509311A5 (cg-RX-API-DMAC7.html)
JP2016539921A5 (cg-RX-API-DMAC7.html)
JP2013543843A5 (cg-RX-API-DMAC7.html)
RU2019116756A (ru) Жидкая фармацевтическая композиция
JP2017516848A5 (cg-RX-API-DMAC7.html)